To strengthen the quality of drugs in India, the Indian Pharmacopoeia Commission (IPC) has released the Addendum 2019 to Indian Pharmacopoeia 2018. Union health minister Dr. Harsh Vardhan officially released the IP Addendum 2019 at a function on 5th July, 2019 at Nirman Bhawan, New Delhi in presence of senior officers of the Health Ministry and scientific staff of the IPC, Ghaziabad.
The IP Addendum 2019 to IP-2018 contains 66 new monographs including those of chemicals (61), herbs and herbal products (03), and radiopharmaceuticals preparations (02). One general monograph on lotion has also been included in this Addendum. Special emphasis has been given to the dosage forms of API whose dosage forms were not in the IP 2018. General chemical tests for identification of an article have been almost eliminated and more specific infrared, ultraviolet spectrophotometric, HPLC and HPTLC tests have been given emphasis. Special emphasis has been given to include/upgrade dissolution test in existing monographs. Most of the existing assays and tests on related substances have been upgraded to liquid chromatography method.
It is hoped that IP Addendum 2019 to IP-2018 would play a significant role in improving the quality of medicines which, in turn, will promote public health and accelerate the growth and development of pharma sector in the country.
On this occasion, Dr. G.N. Singh, Secretary-cum-Scientific Director, IPC highlighted various salient features of IP Addendum 2019 to IP-2018 and emphasized the need of the same with a view to meeting the essential requirements for harmonization of analytical methods with those accepted internationally and said that necessary steps have been taken by the Commission for monitoring and upgrading drug standards in IP Addendum 2019. Further, he also said that publication of IP and its Addendum on regular basis is an important mandate of IPC and is aimed at improving the health of the common man in the country by ensuring the quality, safety and efficacy of medicines.
In the release function, Dr. Vardhan congratulated the IPC and the expert members of the scientific body, IPC staff and various other professionals and organizations for their contributions for achieving this objective. He also recognised that IPC is playing a very pivotal role in this regard to ensure the quality and safety of medicines through science-based tools for well being of patients in the country.
The IP Addendum 2019 to IP-2018 is published by the Indian Pharmacopoeia Commission (IPC) on behalf of the ministry of health & family welfare, Government of India in fulfillment of the requirements of the Drugs and Cosmetics Act, 1940 and the Rules framed thereunder.